share_log

EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target

Benzinga ·  Jun 12, 2023 07:15

EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment